DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Alivus Life Sciences Limited — Analysts/Institutional Investor Meet/Con. Call Updates

NSE 1 hr ago·30 Oct 2026, 9:50 am

Alivus Life Sciences

Alivus Life Sciences Limited has announced that it will hold an institutional investor meeting and an earnings conference call. This event is a scheduled opportunity for the company to discuss its financial performance and future strategy directly with analysts and large investors.

For retail investors, this update signals that the company is preparing to share detailed insights into its business operations. It provides a chance to hear management's perspective on current market conditions and upcoming projects before the information is widely disseminated.

Investors should watch for key details regarding the company's revenue growth, profit margins, and guidance for the upcoming quarters. The conference call transcript will be a valuable resource for understanding management's outlook and assessing the stock's potential.